Searching across hundreds of databases

Our searching services are busy right now. Your search will reload in five seconds.

  • Register
X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X

Leaving Community

Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.

No
Yes
X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

Preparing word cloud

×

Search

Type in a keyword to search

Filter by last modified time
See new records

Current Facets and Filters

  • Related Condition:Breast cancer (facet)
  • Website Status : Ascending

Facets

Sort alphabetically | Sort by count

Recent searches

SciCrunch Registry is a curated repository of scientific resources, with a focus on biomedical resources, including tools, databases, and core facilities - visit SciCrunch to register your resource.

(last updated: Sep 14, 2019)

Physical Resource or Software Tool Software

33 Results - per page

Resource NameResource TypeDescriptionKeywordsResource IDProper CitationParent OrganizationRelated ConditionFunding AgencyRelationReferenceWebsite StatusAlternate IDsAlternate URLsOld URLs
AdaptiveCrawlerResource, software resource, data acquisition software, data processing software, software applicationA web crawler that can intelligently acquire social media content on the Internet to meet the specific online data source acquisition needs of cancer researchers.java, social mediaSCR_000573(AdaptiveCrawler, RRID:SCR_000573)Oak Ridge National Laboratory Cancer, Breast cancer, Lung cancerlisted by: OMICtoolsLast checked downOMICS_01170
Wellcome Trust Case Control ConsortiumResource, data or information resourceConsortium of 50 research groups across the UK to harness the power of newly-available genotyping technologies to improve our understanding of the aetiological basis of several major causes of global disease. The consortium has gathered genotype data for up to 500,000 sites of genome sequence variation (single nucleotide polymorphisms or SNPs) in samples ascertained for the disease phenotypes. Analysis of the genome-wide association data generated has lead to the identification of many SNPs and genes showing evidence of association with disease susceptibility, some of which will be followed up in future studies. In addition, the Consortium has gained important insights into the technical, analytical, methodological and biological aspects of genome-wide association analysis. The core of the study comprised an analysis of 2,000 samples from each of seven diseases (type 1 diabetes, type 2 diabetes, coronary heart disease, hypertension, bipolar disorder, rheumatoid arthritis and Crohn's disease). For each disease, the case samples have been ascertained from sites widely distributed across Great Britain, allowing us to obtain considerable efficiencies by comparing each of these case populations to a common set of 3,000 nationally-ascertained controls also from England, Scotland and Wales. These controls come from two sources: 1,500 are representative samples from the 1958 British Birth Cohort and 1,500 are blood donors recruited by the three national UK Blood Services. One of the questions that the WTCCC study has addressed relates to the relative merits of these alternative strategies for the generation of representative population cohorts. Genotyping for this main Case Control study was conducted by Affymetrix using the (commercial) Affymetrix 500K chip. As part of this study a total of 17,000 samples were typed for 500,000 SNPs. There are two additional components to the study. First, the WTCCC award is part-funding a study of host resistance to infectious diseases in African populations. The same approach has been used to type 2,000 cases of tuberculosis (TB) and 2,000 cases of malaria, as well as 2,000 shared controls. As well as addressing diseases of major global significance, and extending WTCCC coverage into the area of infectious disease, the inclusion of samples of African origin has obvious benefits with respect to methodological aspects of genome-wide association analysis. Second, the WTCCC has, for four additional diseases (autoimmune thyroid disease, breast cancer, ankylosing spondylitis, multiple sclerosis), completed an analysis of 15,000 SNPs designed to represent a large proportion of the known non-synonymous coding SNPs across the genome. This analysis has been performed at the WTSI using a custom Infinium chip (Illumina). Data release The genotypic data of the control samples (1958 British Birth Cohort and UK Blood Service) and from seven diseases analyzed in the main study are now available to qualified researchers. Summary genotype statistics for these collections are available directly from the website. Access to the individual-level genotype data and summary genotype statistics is by application to the Consortium Data Access Committee (CDAC) and approval subject to a Data Access Agreement. WTCCC2: A further round of GWA studies were funded in April 2008. These include 15 WTCCC-collaborative studies and 12 independent studies be supported totaling approximately 120,000 samples. Many of the studies represent major international collaborative networks that have together assembled large sample collections. WTCCC2 will perform genome-wide association studies in 13 disease conditions: Ankylosing spondylitis, Barrett's oesophagus and oesophageal adenocarcinoma, glaucoma, ischaemic stroke, multiple sclerosis, pre-eclampsia, Parkinson's disease, psychosis endophenotypes, psoriasis, schizophrenia, ulcerative colitis and visceral leishmaniasis. WTCCC2 will also investigate the genetics of reading and mathematics abilities in children and the pharmacogenomics of statin response. Over 60,000 samples will be analyzed using either the Affymetrix v6.0 chip or the Illumina 660K chip. The WTCCC2 will also genotype 3,000 controls each from the 1958 British Birth cohort and the UK Blood Service control group, and the 6,000 controls will be genotyped on both the Affymetrix v6.0 and Illumina 1.2M chips. WTCCC3: The Wellcome Trust has provided support for a further round of GWA studies in January 2009. These include 5 WTCCC-collaborative studies to be carried out in WTCCC3 and 5 independent studies, across a range of diseases. Many of the studies represent major international collaborative networks that have together assembled large sample collections. WTCCC3 will perform genome-wide association studies in the following 4 disease conditions: primary biliary cirrhosis, anorexia nervosa, pre-eclampsia in UK subjects, and the interactions between donor and recipient DNA related to early and late renal transplant dysfunction. The WTCCC3 will also carry out a pilot in a study of the genetics of host control of HIV-1 infection. Over 40,000 samples will be analyzed using the Illumina 660K chip. The WTCCC3 will utilize the 6,000 control genotypes generated by the WTCCC2.gene, genomic, genetics, microarray, genome-wide association study, snp, genome-wide association, blood, dna, genotype, variation, genome, sequence variant, copy number variation, genetic variation, phenotype, diseaseSCR_001973(Wellcome Trust Case Control Consortium, RRID:SCR_001973)Wellcome Trust Sanger Institute; Hinxton; United Kingdom Bipolar Disorder, Coronary artery disease, Crohn's disease, Rheumatoid arthritis, Type 1 diabetes, Type 2 diabetes, Hypertension, Control, Multiple sclerosis, Breast cancer, Ankylosing spondylitis, Autoimmune thyroid disease, Malaria, Tuberculosis, Inflammatory bowel disease, Barrett's esophagus, Esophageal adenocarcinoma, Glaucoma, Ischemic stroke, Pre-eclampsia, Parkinson's disease, Psychosis endophenotypes, Psoriasis, Schizophrenia, Ulcerative colitis, Visceral leishmaniasis, Primary biliary cirrhosis, Anorexia nervosa, Human immunodeficiency virus, Renal transplant dysfunctionBill and Melinda Gates Foundation, Wellcome Trust, Wellcome Trust Sanger Institute; Hinxton; United Kingdomrelated to: Psychiatric Genomics ConsortiumPMID:17554300Last checked downnif-0000-10551
GSE1456Resource, data set, data or information resourceCurated series of expression data for 159 tumors from which RNA could be collected in sufficient amounts and quality for analysis from breast cancer patients. Tissue material was collected from all breast cancer patients receiving surgery at Karolinska Hospital from 1994-1996.adult human, breastSCR_003642(GSE1456, RRID:SCR_003642)RanchoBiosciences Breast cancer, Tumorrelated to: Gene Expression OmnibusLast checked downnlx_157793
GSE4922Resource, data set, data or information resourceCurated data set of a study that investigated the expression profiles of 347 primary invasive breast tumors on Affymetrix microarrays. Three separate breast cancer cohorts were analyzed: 1) Uppsala (n=249), 2) Stockholm (n=58), 3) Singapore (n=40). The Uppsala and Singapore data can be accessed in GSE4922. The Stockholm cohort data can be accessed at GEO Series GSE1456.adult human, expression profile, breastSCR_003557(GSE4922, RRID:SCR_003557)RanchoBiosciences Cancer, Breast cancer, Tumorrelated to: Gene Expression OmnibusLast checked downnlx_157796
GSE20194Resource, data set, data or information resourceCurated data set of gene expression data from 230 stage I-III breast cancers that were generated from fine needle aspiration specimens of newly diagnosed breast cancers before any therapy. The biopsy specimens were collected sequentially during a prospective pharmacogenomic marker discovery study between 2000 and 2008. These specimens represent 70-90% pure neoplastic cells with minimal stromal contamination. In the study, patients received 6 months of preoperative (neoadjuvant) chemotherapy including paclitaxel, 5-fluorouracil, cyclophosphamide and doxorubicin followed by surgical resection of the cancer.gene expression, chemotherapy, paclitaxel, 5-fluorouracil, cyclophosphamide, doxorubicin, adult humanSCR_003645(GSE20194, RRID:SCR_003645)RanchoBiosciences Cancer, Breast cancerrelated to: Gene Expression OmnibusLast checked downnlx_157797
Cancer Center Tissue Bank - Fudan UniversityResource, biomaterial supply resource, material resource, tissue bankThe Institutional Tissue Bank (ITB) of Fudan University Shanghai Cancer Center was established in 2006 with the goal of serving as a central repository for human tissue samples for cancer research and possible personalized medicine for the institution. The Institutional Research Board oversees the fulfilling of informed consent of each patient whose samples are collected. The ITB''s collection procedures meet the global quality standards and provide high quality tissue samples. The quality control for morphology, RNA, DNA and protein has been set up to ensure the sample quality. Routine frozen section from tissue aliquot is made for every piece of sample to ensure the component of tumor tissue and the pathological feature is the same as the diagnosed tumor. Agilent 2100 Bioanalyzer was used to provide RNA and DNA quality parameters. The Tissue Bank occupies 500 m2, with sufficient space for sample preparation and storage, data registration, data tracking/access, related equipments and monitor system. Variant samples including blood, tumor tissue, and body fluids are collected and serve as alternative permanent patient tissue records. Annotation of collected samples is captured through linking the medical record and pathological report system to tissue bank software. Frequent tumor types such as lung cancer, breast cancer, gastric cancer, urological tumors, gynecological tumors and esophageal cancers, head & neck cancers, as well as infrequent cancer types such as malignant soft tissue sarcomas, pancreatic cancer, gall bladder cancer, and other rare cancers are all collected and stored. Tumor tissues are stored with matched normal tissues. Serum and plasma are isolated from coagulation plus and coagulation minus blood samples. White blood cells are stored as well. Tissues are stored both in RNALater at -20 degrees C and -80 degrees C after snap frozen. Samples have been increased from 4,000 in 2008 to 10,783 in 2009. To the end of September 2010, over 30,000 samples has been processed and stored in our tissue bank. As planned, 50,000 samples will be stored dynamically. Over 50 funded projects have used the samples from our tissue bank. Productive papers have been published in the past years by using the samples. More and more projects will be approved to get research resources from tissue bank in the future. The tissue bank of FUSCC has been designated as the key subject and successful model by Shanghai municipal government.blood, tumor tissue, body fluids, cancer, normal tissue, serum, plasma, white blood cells, snap frozen, lung cancer, breast cancer, gastric cancer, urological tumor, gynecological tumor, esophageal cancer, head cancer, neck cancer, malignant soft tissue sarcomas, pancreatic cancer, gall bladder cancer, rare cancer, matched normal tissueSCR_004596(Cancer Center Tissue Bank - Fudan University, RRID:SCR_004596)Fudan University; Shanghai; China Cancer, Lung cancer, Breast cancer, Gastric cancer, Urological tumor, Gynecological tumor, Esophageal cancer, Head cancer, Neck cancer, Malignant soft tissue sarcomas, Pancreatic cancer, Gall bladder cancer, Rare cancer, Matched normal tissuelisted by: One Mind Biospecimen Bank ListingLast checked downnlx_59788http://www.shca.org.cn/eng/content.asp?ArticleID=63
Susan G. Komen Tissue BankResource, biomaterial supply resource, material resource, tissue bankThe goals of the Susan G. Komen for the Cure Tissue Bank at the IU Simon Cancer Center are to acquire biomolecule and tissue specimens from the entire continuum of breast development: puberty to menopause and to make these specimens or the digital data derived from them available and accessible to researchers across the globe.SCR_004708(Susan G. Komen Tissue Bank, RRID:SCR_004708) Susan G. Komen for the Cure , Indiana University; Indiana; USA Breast cancerlisted by: One Mind Biospecimen Bank ListingLast checked downnlx_70500
Tumorbank Basel FoundationResource, database, biomaterial supply resource, tissue bank, service resource, storage service resource, material storage repository, material resource, data or information resourceSince 1995 the Tumorbank Basel Foundation (German: Stiftung Tumorbank Basel) is a non-for-profit foundation acting in cancer translation research. The purpose of the Tumorbank Basel Foundation is to support in promoting optimization of decision making process for the management of solid cancer personalized treatment modalities to the benefit of the patient. Our Aims: * Acquisition and storage of biological material and clinical data of patients suffering of solid cancer diseases in particular breast and prostate cancer. * Promoting and supporting cancer research using the acquired material and data for clinical studies and translational research. * The development of molecular tumor analyses / tools for cancer patients and the performance of the resulting diagnostic services for personalized treatment modalities. The Tumorbank Basel Foundation has acquired * Data about more than 10''000 breast cancer patients * Data comprise clinical and pathological (histology & IHC) characteristics and biochemical (continuous quantified protein expression levels) features, which are available for almost all samples as well as clinical follow-ups now available for more than 2''000 patients * The RNA expression level of 65 genes has been assessed in >800 samples by Real-Time PCR (317 retrospectively in cases with follow-up, the remaining on a routine basis, prospectively since 2004) The Tumorbank Basel Foundation is storing in Freezers at - 80 degrees C * Ca. 6''000 fresh frozen tissue samples of breast cancer patients * Ca. 9''000 particulate fractions (cytosol / membrane) of all samples analyzed * Ca. 1''000 paired non-malignant adjacent tissue material samples * More than 1''000 extracted RNA samples of good quality * Serum and plasma collection from patients has been started since 2005 All data are stored in a relational SQL data bank using an application. The Tumorbank Basel Foundation is collaborating with several pathology institutes allowing to perform studies correlating results obtained from fresh frozen and paired paraffin embedded tissue samples. The Tumorbank Basel Foundation has started a prostate carcinoma project in Collaboration with the ZeTuP (www.zetup.ch) and pathology institute of St. Gallen. Fresh frozen samples of more than 150 prostate carcinoma patients have been collected and are under investigation.tissue, tumor tissue, serum, plasma, rna, particulate fraction, clinical data, frozen, fresh frozen, paraffin embedded, cancer, breast cancer, prostate cancer, solid cancer diseaseSCR_004962(Tumorbank Basel Foundation, RRID:SCR_004962)Cancer, Breast cancer, Prostate cancer, Solid cancer diseaselisted by: One Mind Biospecimen Bank ListingLast checked downnlx_143986
LIBRO-1: Individualized prediction and prevention of breast cancerResource, disease-related portal, topical portal, research forum portal, biomaterial supply resource, portal, material resource, data or information resourceTHIS RESOURCE IS NO LONGER IN SERVICE, documented August 23, 2016. Libro-1 is a study with the overall aim to identify prognostic factors for breast cancer. The study comprise women in the Stockholm-Gotland region that were diagnosed with breast cancer between the years 2001-2008. Register data (tumor characteristics and treatment), lifestyle factors and blood samples have been collected from the participants.breast, cancer, tumor, treatment, woman, female, lifestyle, prognostic factor, prediction, preventionSCR_006036(LIBRO-1: Individualized prediction and prevention of breast cancer, RRID:SCR_006036)Karolisnka Biobank Breast cancerlisted by: One Mind Biospecimen Bank ListingLast checked downnlx_151436
University of Michigan Human Breast Cancer Cell LinesResource, service resource, production service resource, biomaterial manufacture, material service resourceAsterand, Inc., the Detroit-based supplier of human tissue products and services, announces the distribution of eleven breast cancer cell lines, derived at the University of Michigan. The University has agreed to license the marketing of the breast cancer cell lines, known as the SUM lines, through Asterand in an effort to provide an exceptional tool to a broad base of researchers studying the disease. There are an estimated 1.2 million new diagnoses worldwide of breast cancer each year. The cell lines can be used to study all aspects of breast cancer biology, from new drug target identification to cell signaling to effects of novel drugs on cellular proliferation.cell line, breast cancerSCR_000542(University of Michigan Human Breast Cancer Cell Lines, RRID:SCR_000542)University of Michigan Medical School; Michigan; USA Breast cancerrelated to: AsterandLast checked upnlx_84393
Sullivan Lab Evidence ProjectResource, data or information resource, databaseDatabase of genetic and gene expression data from the published literature on psychiatric disorders. Users can search the accumulated data to find the evidence in support of the involvement of a particular genomic region with a set of important psychiatric disorders, ADHD, autism, bipolar disorder, eating disorder, major depressive disorder, schizophrenia, and smoking behavior. It contains findings from manual reviews of 144 papers in psychiatric genetics, 136 primary reports and 8 meta-analyses. Disorders covered include schizophrenia (44 papers), autism (24 papers), bipolar disorder (24 papers), smoking behavior (24 papers), major depressive disorder and neuroticism (14 papers), ADHD (8 papers), eating disorders (3 papers), and a combined schizophrenia-bipolar phenotype (3 papers). The unbiased searches integrated into SLEP include genomewide linkage (117 papers), genomewide association (15 papers), copy number variation (9 papers), and gene expression studies of post-mortem brain tissue (3 meta-analyses courtesy of the Stanley Foundation). In total, SLEP captures 3,741 findings from these 144 papers. SLEP also contains over 70,000 SignPosts. These annotations derive from many different sources and are designed to try to capture current state of knowledge about disease associations in the human genome. SignPosts can be searched simultaneously with the psychiatric genetics literature in order to integrate these two bodies of knowledge. The SignPosts include: accumulated GWAS findings from the human genetics literature, the OMIM database, candidate gene association study literature, CNV location and frequency data, SNPs that influence gene expression in brain, genes expressed in brain, genes with evidence of imprinting and random monoalleleic expression, genes mutated in breast or colorectal cancer, and pathway data from BioCyc.eating disorder, gene, gene expression, adhd, autism, bipolar disorder, brain, breast, cancer, colorectal, combined schizophrenia-bipolar, disease, genomic region, imprinting, major depressive disorder, meta-analysis, monoalleleic, mutation, neuroticism, post-mortem, psychiatric disorder, schizophrenia, smoking behavior, tissue, molecular neuroanatomy resourceSCR_000753(Sullivan Lab Evidence Project, RRID:SCR_000753)Eating disorder, Bipolar disorder, Brain, Breast cancer, Colorectal cancer, Combined schizophrenia-bipolar disease, Genomic region, Imprinting, Major depressive disorder, schizophrenia, Smoking behavior, Autism, Attention deficit-hyperactivity disorderNIMHLast checked upnif-0000-10439
Eligibility Feature HierarchyResource, ontology, data or information resource, controlled vocabularyA set of 1,437 eligibility features that were organized into a feature hierarchy using 80 breast cancer trials.owlSCR_010314(Eligibility Feature Hierarchy, RRID:SCR_010314)Breast cancerlisted by: BioPortalLast checked upnlx_157395
The Cancer Genome AtlasResource, biomaterial supply resource, biospecimen repository, data set, service resource, portal, storage service resource, material storage repository, material resource, data or information resourceProject exploring the spectrum of genomic changes involved in more than 20 types of human cancer that provides a platform for researchers to search, download, and analyze data sets generated. As a pilot project it confirmed that an atlas of changes could be created for specific cancer types. It also showed that a national network of research and technology teams working on distinct but related projects could pool the results of their efforts, create an economy of scale and develop an infrastructure for making the data publicly accessible. Its success committed resources to collect and characterize more than 20 additional tumor types. Components of the TCGA Research Network: * Biospecimen Core Resource (BCR); Tissue samples are carefully cataloged, processed, checked for quality and stored, complete with important medical information about the patient. * Genome Characterization Centers (GCCs); Several technologies will be used to analyze genomic changes involved in cancer. The genomic changes that are identified will be further studied by the Genome Sequencing Centers. * Genome Sequencing Centers (GSCs); High-throughput Genome Sequencing Centers will identify the changes in DNA sequences that are associated with specific types of cancer. * Proteome Characterization Centers (PCCs); The centers, a component of NCI's Clinical Proteomic Tumor Analysis Consortium, will ascertain and analyze the total proteomic content of a subset of TCGA samples. * Data Coordinating Center (DCC); The information that is generated by TCGA will be centrally managed at the DCC and entered into the TCGA Data Portal and Cancer Genomics Hub as it becomes available. Centralization of data facilitates data transfer between the network and the research community, and makes data analysis more efficient. The DCC manages the TCGA Data Portal. * Cancer Genomics Hub (CGHub); Lower level sequence data will be deposited into a secure repository. This database stores cancer genome sequences and alignments. * Genome Data Analysis Centers (GDACs) - Immense amounts of data from array and second-generation sequencing technologies must be integrated across thousands of samples. These centers will provide novel informatics tools to the entire research community to facilitate broader use of TCGA data. TCGA is actively developing a network of collaborators who are able to provide samples that are collected retrospectively (tissues that had already been collected and stored) or prospectively (tissues that will be collected in the future).genome, genome sequencing, breast, central nervous system, endocrine, gastrointestinal, gynecologic, head, neck, hematologic, skin, soft tissue, thoracic, urologic, clinical, genomic characterization, analysis, tumor genome, demographic, gene expression, copy number alteration, epigenetic, dna sequence, exome, snp, methylation, mrna, mirnaSCR_003193(The Cancer Genome Atlas, RRID:SCR_003193)National Cancer Institute Cancer, Tumor, Normal, Breast cancer, Central Nervous System cancer, Endocrine cancer, Gastrointestinal cancer, Gynecologic cancer, Head cancer, Neck cancer, Hematologic cancer, Skin cancer, Soft tissue cancer, Thoracic cancer, Urologic cancerNCIrelated to: Cancer3D, used by: Mutation Annotation and Genomic Interpretation, BioXpress, listed by: One Mind Biospecimen Bank ListingLast checked upnlx_156913
OrionResource, portal, organization portal, commercial organization, data or information resourceA globally operating Finnish developer, manufacturer and marketer of human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. They are continuously developing new drugs and treatment methods. Pharmaceutical RD focuses on central nervous system drugs, oncology and critical care drugs, and Easyhaler pulmonary drugs.pharmaceutical, drug, diagnostic test, diagnostic, central nervous system, drug, oncology, critical care, pulmonary, central nervous system drug, pulmonary drug, cancer, veterinary drug, medicine, clinical, hygiene monitoringSCR_003911(Orion, RRID:SCR_003911)Cancer, Asthma, Alzheimer's disease, Parkinson's disease, Breast cancer, Prostate cancerrelated to: MIP-DILI, NEWMEDS, ORBITO, PREDECTLast checked upnlx_158257
DCI Tissue and Blood Procurement Shared ResourceResource, biomaterial supply resource, material resource, tissue bankTHIS RESOURCE IS NO LONGER IN SERVICE, documented on July 16, 2013. Over 10,000 patient consents, 5,000 banking events, and 40,000 biospecimens have been processed to date with storage of both formalin fixed paraffin embedded (FFPE) tissue and frozen tissue located within multiple freezers spanning temperatures in the range of -80 degrees to -180 degrees C depending on protocol requirements. Considerable effort continues to be expended to assure compliance with IRB, NIH and HIPAA best practices and guidelines on banking human tissues. The biorepository in place today is the result of the combined efforts of the Duke Cancer Institute (DCI) Breast SPORE, DCI Shared Resource for Tissue and Blood Procurement, and the Duke University School of Medicine Research Foundation (DUSOM-RF). The DCI and the School of Medicine Research Foundation (SOMRF) have funded the collection of frozen and fixed tissues, both malignant and benign, under an ?????????????????excess tissue????????????????? protocol that utilizes freshly excised tissue that is available for research after the needs of the pathologic workup are met. This program procures tissues from many anatomic sites including breast. Recently Duke''s Institute of Genome Science & Policy (IGSP), under the direction of Drs. Geoff Ginsburg and Tom Burke, initiated a blood collection program that spans several departments and institutes. The Breast SPORE blood collection program served as the pilot for this much larger effort. The Breast SPORE tissue and blood collection effort utilizes much of the same infrastructure and personnel that are also supported by the DCI, SOMRF, and IGSP.blood, tissue, cancer, biospecimen, formalin fixed paraffin embedded tissue, frozen tissue, malignant, benign, breast tissue, breast cancer, tumor, frozen, paraffin, malignant tissue, benign tissueSCR_004116(DCI Tissue and Blood Procurement Shared Resource, RRID:SCR_004116)Duke Cancer Institute Cancer, Breast cancer, Malignant tumor, Benign tumorlisted by: One Mind Biospecimen Bank ListingLast checked upnlx_19619http://www.cancer.duke.edu/modules/SPORE50/index.php?id=5
Canadian Breast Cancer Foundation Tumor BankResource, biomaterial supply resource, biospecimen repository, tissue bank, service resource, storage service resource, data or information resource, material resource, material storage repositoryA tumor bank that provides a large collection of cancer specimens, from breast and other cancers, annotated with clinical information. The CBCF TB enables researchers to address unanswered questions concerning the prognosis and treatment of breast cancer and other cancers. The CBCF TB website is also directed to participants interested in donating tumor tissue or blood. Biological specimens such as blood, urine, bone marrow, and ascites (fluid that sometimes collects in the abdomen) contain genetic information, just as tumor tissue does. These samples can be used in studies that may help researchers see how people with certain genetic make-ups respond to certain treatments. It can also explain why different people have different health problems. CBCF TB, formerly ARTB, was created by a merger of components of two existing Tumor-banking initiatives, the CLS Repository in Calgary and the Tumor bank of the PolyomX Program in Edmonton.clinical information, clinicalSCR_004214(Canadian Breast Cancer Foundation Tumor Bank, RRID:SCR_004214)Canadian Breast Cancer Foundation Breast cancer, Tumor, CancerAlberta Cancer Foundation, Canadian Breast Cancer Foundationrelated to: Canadian Tumour Repository Network, listed by: One Mind Biospecimen Bank ListingLast checked upnlx_143637
Biobank GrazResource, production service resource, analysis service resource, biomaterial supply resource, tissue bank, service resource, material resource, data or information resourceBiobank Graz is a non-profit central Medical University of Graz (MUG) service facility that provides the logistics and infrastructure to optimally support MUG research teams in the collection, processing and storage of biological samples and their associated data. In the course of this, special attention is given to sample and data quality and to the protection of the individual rights of patients. Samples from selected patients at the Graz LKH-University Clinical Centre, who have signed an informed consent declaration, are deposited in Biobank Graz. This means that excess tissue and blood samples are collected and placed in storage. The samples are harvested in the course of routine interventions undertaken by the different departments and institutes of the Graz LKH-University Clinical Centre and approved for use in research projects only after the completion of all necessary laboratory and histopathological analyses. No additional material is removed: in other words, there are no associated drawbacks whatsoever for the patients involved. Biobank Graz operates a quality management system according to ISO 9001:2008 and offers the following services for the processing and storage of biological samples and the handling of data: * Consistently high sample quality through the processing of samples using standardized methods in accordance with written working instructions (SOPs) * Efficient use of resources through the building of shared infrastructure and the development of optimized processes * A high degree of reliability provided by the storage of samples in 24/7 - monitored storage systems. * Processing and storage of all data in accordance with data protection legislation. Biobank Graz comprises both population-based and disease-focused collections of biological materials. It currently contains approx. 3.8 mio samples from approx. 1.2 mio patients representing a nonselected patient group characteristic of central Europe. Because the Institute of Pathology was, until 2003, the exclusive pathology service provider for major parts of the province of Styria, including its capital Graz (population approx. 1.2 mio people), samples from all human diseases, treated by surgery or diagnosed by biopsy, are included in the collection at their natural frequency of occurrence and thus represent cancers and non-cancerous diseases from all organs, and from all age groups. The scientific value of the existing tissue collection is, thus, not only determined by its size and technical homogeneity (all samples have been processed in a single institute under constant conditions for more than 20 years), but also by its population-based character. These features provide ideal opportunities for epidemiological studies and allow the validation of biomarkers for the identification of specific diseases and determination of their response to treatment. Prospectively collected tissues, blood samples and clinical data comprise, on the one hand, randomly selected samples from all diseases and patient groups to provide sufficient numbers of samples for the evaluation of the disease-specificity of any gene or biomarker. On the other hand, Biobank Graz adopts a disease-focused approach for selected diseases (such as breast, colon and liver cancers as well as some metabolic diseases) through the collection of a range of different human biological samples of highest quality and detailed clinical follow-up data. Graz Medical University established the Biobank to provide improved and sustainable access to biological samples and related (clinical) data both for its own academic research and for external research projects of academic and industrial partners. It is a major interest of the university to initiate co-operative research projects. Biological samples and data are available to external institutions performing high-quality research projects which comply with the Biobank''s ethical and legal framework according to the access rules (Contact: COO Karine Sargsyan, MD, PhD).tissue, blood, dna, rna, serum, plasma, bodily fluid, urine, cryopreserved, formalin fixed paraffin embedded, csf, frozen, disease, population, patient, healthy, normal, clinical, patient, healthy, normal, disease, cancer, metabolic disease, breast cancer, colon cancer, liver cancer, clinical data, cerebral spinal fluidSCR_004245(Biobank Graz, RRID:SCR_004245)Medical University of Graz; Graz; Austria All, Patient, Healthy, Normal, Disease, Cancer, Metabolic disease, Breast cancer, Colon cancer, Liver cancerlisted by: One Mind Biospecimen Bank ListingLast checked upnlx_25894
Ludwig Boltzman Tumour BankResource, biomaterial supply resource, material resource, tissue bank, data or information resourceAs a basis for the experimental cluster projects, and for further future projects a collection of various biological specimens of cancer patients shall be established. All participating Ludwig Boltzmann Institutes (LBIs) are supplying biological specimens from tumor patients and clinical documentation. At the LBI for Gynecology and Gynecologic Oncology a tumor bank for biological specimens from gynecologic cancer patients already exists. All the procedures for sample processing and storage are well established. Existing equipment for storing tissue specimens at -196 degrees C can be used. Materials from the following malignant diseases are collected: Breast cancer Colorectal cancer Neuroendocrine tumors (NET) (Small cell lung cancer (SCLC) and Carcinoid tumors) Types of biological materials: Tissue (fresh frozen) Bone marrow Blood (serum/plasma/cell fractions) Pleural effusions Ascitic fluids Sputum Bronchial lavage Stool The biological specimens are initially processed at the respective LBIs or at their connected lab facilities. Enrichment of blood samples for disseminated tumor cells is done at the LBI for Gynecology and Gynecologic oncology. Long time storage of all materials is done at appropriate temperatures at the same institution. This LBI also coordinates the logistics. All relevant sample-specific and clinical data are surveyed at the respective LBIs and stored centralized in an on-line data bank in anonymized form, respecting all relevant regulations on data protection and security.tissue, bone marrow, blood, serum, plasma, cell fraction, pleural effusion, ascitic fluid, sputum, bronchial lavage, stool, tumor cell, fresh frozen, frozen, tumor, cancer, breast cancer, colorectal cancer, neuroendocrine tumor, small cell lung cancer, carcinoid tumor, gynecologic cancer, clinical data, bodily fluidSCR_004322(Ludwig Boltzman Tumour Bank, RRID:SCR_004322)Ludwig Boltzmann Cluster Translationale Onkologie Tumor, Cancer, Breast cancer, Colorectal cancer, Neuroendocrine tumor, Small cell lung cancer, Carcinoid tumor, Gynecologic cancerlisted by: One Mind Biospecimen Bank ListingLast checked upnlx_33431
National Surgical Adjuvant Breast and Bowel Project Tissue BankResource, biomaterial supply resource, material resource, tissue bank, data or information resourceThe NSABP (National Surgical Adjuvant Breast and Bowel Project) Tissue Bank is the central repository of tissue samples (stained and unstained slides, tissue blocks, and frozen tissue specimens) collected from clinical trials conducted by the NSABP. The main scientific aim of the NSABP Division of Pathology is to develop clinical context-specific prognostic markers and predictive markers that predict response to or benefit from specific therapeutic modality. To achieve this aim, the laboratory collects the tumor and adjacent normal tissues from cancer patients enrolled into the NSABP trials through its membership institutions, and maintain these valuable materials with clinical follow-up information and distribute them to qualified approved investigators. Currently, specimens from more than 90,000 cases of breast and colon cancer are stored and maintained at the bank. Paraffin embedded tumor specimens are available from NSABP trials. We currently do not bank frozen tissues. All blocks are from patients enrolled in prospective NSABP treatment protocols and complete clinical follow up information as well as demographic information is available. Depending on the project, unstained tissue sections of 4-micrometer thickness, tissue microarrays, or stained slides are provided to the investigators in a blinded study format. Any investigators with novel projects that conform to the research goals of NSABP may apply for the tissue. Please refer to the NSABP Tissue Bank Policy to determine if your project conforms to these goals. Priority is given to NSABP membership institutions who regularly submit tissue blocks.clinical, clinical data, demographic data, tumor, specimen, breast tissue, bowel tissue, tumor tissue, adjacent normal tissue, tissue, stained slide, unstained slide, tissue block, paraffin embedded, tissue microarray, cancer, breast cancer, colon cancer, normalSCR_004506(National Surgical Adjuvant Breast and Bowel Project Tissue Bank, RRID:SCR_004506)University of Pittsburgh; Pennsylvania; USA Cancer, Breast cancer, Colon cancerNCIlisted by: One Mind Biospecimen Bank ListingLast checked upnlx_48875http://www.nsabp.pitt.edu/NSABP_Pathology.asp#2.%20Tissue%20Bank
Cancer Control using Population-based Registries and BiobanksResource, training resource, biomaterial supply resource, standard specification, narrative resource, portal, material resource, data or information resourceCCPRB (Cancer Control using Population-based Registries and Biobanks) is a Network of Excellence project within the sixth framework programme of the European Union. It is aiming at improved control of cancer by facilitating research linking biobanks and cancer registries. The project involves a systematic quality assurance and continuous development of standards and norms for human sample biobanks in Europe, as well as development of improved integrity-protection standards in the handling of sensitive information in connection with biobank-based research. The samples in the biobanks will be used in large-scale cancer research searching for genetic and infectious causes to cancer, in particular in the areas of breast and colorectal cancer and childhood leukemia. Project objectives: * Provide the study base for uniquely large population-based prospective studies on cancer * Define and implement a generally applicable European Quality Standard for Biobanking that will include improved data and specimen standardization, acquisition and analysis, reliable and standardized statistical analysis as well as improved management and co-ordination of European biobanks. * Define and promote the implementation of integrity-proof methods for biobank-based research involving well defined and secure third party code-keeping systems. * Enable large-scale, population-based research on: ** evaluation of cancer treatment and role of molecular markers in treatment selection ** use over-generation registry linkages applied to large biobank cohorts to identify and evaluate genetic predisposition associated with increased cancer risk as well as interactions with common environmental exposures. ** use over-generation registry linkages applied to large biobank cohorts to explore and evaluate intrauterine exposures associated with increased cancer risk ** exploit the power of large population cohorts for design of optimal strategies for cancer prevention and its evaluation. * Establish a Europe-wide network for spreading the awareness of i) the data, samples and knowledge generated European biobank-based research ii) possibilities for future biobank-based research and iii) the best practice quality standards for biobank-based research.genetic, infectious disease, young human, child, registry, biobankSCR_004902(Cancer Control using Population-based Registries and Biobanks, RRID:SCR_004902)Lund University; Lund; Sweden Cancer, Breast cancer, Colorectal cancer, Childhood leukemia, LeukemiaEuropean Union FP6listed by: One Mind Biospecimen Bank ListingLast checked upnlx_87258
X
  1. RRID Portal Resources

    Welcome to the RRID Resources search. From here you can search through a compilation of resources used by RRID and see how data is organized within our community.

  2. Navigation

    You are currently on the Community Resources tab looking through categories and sources that RRID has compiled. You can navigate through those categories from here or change to a different tab to execute your search through. Each tab gives a different perspective on data.

  3. Logging in and Registering

    If you have an account on RRID then you can log in from here to get additional features in RRID such as Collections, Saved Searches, and managing Resources.

  4. Searching

    Here is the search term that is being executed, you can type in anything you want to search for. Some tips to help searching:

    1. Use quotes around phrases you want to match exactly
    2. You can manually AND and OR terms to change how we search between words
    3. You can add "-" to terms to make sure no results return with that term in them (ex. Cerebellum -CA1)
    4. You can add "+" to terms to require they be in the data
    5. Using autocomplete specifies which branch of our semantics you with to search and can help refine your search
  5. Collections

    If you are logged into RRID you can add data records to your collections to create custom spreadsheets across multiple sources of data.

  6. Facets

    Here are the facets that you can filter the data by.

  7. Further Questions

    If you have any further questions please check out our FAQs Page to ask questions and see our tutorials. Click this button to view this tutorial again.